Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma
Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation...



